Bayer AG BAYRY reported first-quarter 2025 core earnings of 66 cents per American Depositary Receipt (ADR), beating the Zacks Consensus Estimates of 63 cents. The company reported earnings of 77 cents ...

EYLEA HD is supported by a robust body of research ... and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's ...

whether Regeneron will ultimately be able to obtain FDA approval for additional extended dosing intervals for EYLEA HD and, if so, the timing of any such approval; the likelihood, timing, and scope of ...

EYLEA HD is approved with dosing intervals from ... and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products ...

EYLEA HD is approved with dosing intervals from ... and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s ...

This agreement enables the company to launch in the United States in the ... As the first-to-file interchangeable biosimilar to Eylea, Yesafili affirms our scientific strength and marks our ...

This agreement enables the company to launch in the US in the second half of calendar year ... As the first-to-file interchangeable biosimilar to Eylea, Yesafili affirms our scientific strength and ...

Only a month ago, Opthea was making preparations for the potential launch of a new eye disease drug onto the market. Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these ...

Upon signature of the agreement, Klinge will receive upfront payments and is eligible to receive milestone payments on launch and sales ... and to add AHZANTIVE ® (aflibercept), a biosimilar to Eylea ...

REGN filed an application with the FDA for the use of the Eylea HD pre-filled syringe (PFS). A potential approval and launch are expected by mid 2025. Longer-term data in wet age-related macular ...